Get the Stockscreener App
0.4542
1.30%
-0.006
After Hours:
.47
0.0158
+3.48%
Curanex Pharmaceuticals Inc stock is traded at $0.4542, with a volume of 106.14K.
It is down -1.30% in the last 24 hours and down -21.13% over the past month.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
See More
Previous Close:
$0.4602
Open:
$0.489
24h Volume:
106.14K
Relative Volume:
0.07
Market Cap:
$12.87M
Revenue:
-
Net Income/Loss:
$-435.00K
P/E Ratio:
-28.93
EPS:
-0.0157
Net Cash Flow:
$-665.30K
1W Performance:
+4.41%
1M Performance:
-21.13%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.445
$0.489
1-Week Range:
$0.4306
$0.4922
52-Week Range:
$0.376
$9.1796
Curanex Pharmaceuticals Inc Stock (CURX) Company Profile
Name
Curanex Pharmaceuticals Inc
Sector
Industry
Phone
718-673-6078
Address
2 JERICHO PLAZA,, JERICHO
Compare CURX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CURX
Curanex Pharmaceuticals Inc
|
0.4542 | 13.04M | 0 | -435.00K | -665.30K | -0.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Curanex Pharmaceuticals Inc Stock (CURX) Latest News
Curanex Pharmaceuticals Inc (CURX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Weekly Research Analysts’ Ratings Updates for Curanex Pharmaceuticals (CURX) - Defense World
Curanex Pharmaceuticals Inc (CURX) is looking forward to a strong quarter - setenews.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Curanex Pharmaceuticals Faces Nasdaq Delisting Warning - MSN
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Wall Street Zen Downgrades Curanex Pharmaceuticals (NASDAQ:CURX) to Sell - Defense World
Curanex Pharmaceuticals Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com
Curanex Pharmaceuticals Inc SEC 10-Q Report - TradingView
Curanex Pharmaceuticals receives Nasdaq notice on minimum bid price requirement - Investing.com India
Curanex Pharmaceuticals IncCommon Stock (NQ: CURX - FinancialContent
Curanex engages Strategic Investor Relations to enhance Curanex’s visibility - MSN
Curanex Pharmaceuticals (CURX): An Emerging Force in US Botanical Drug Development - Markets Financial Content
Curanex Pharmaceuticals (CURX): An Emerging Force In US Botanical Drug Development - Menafn.com
Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement - The Manila Times
Curanex Pharmaceuticals Inc. Engages Strategic Investor - GlobeNewswire
Curanex (Nasdaq: CURX) engages Strategic Investor Relations; UC lead IND targeted in 2026 - Stock Titan
Price performance - Yahoo
Curanex Pharmaceuticals Inc trading resumes - MSN
Curanex Pharmaceuticals Issues Shares Post-IPO - TipRanks
Curanex Pharmaceuticals issues shares in private placement and repays insider loans - Investing.com
Curanex Pharmaceuticals Inc Stock (CURX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):